logo
logo

Stilla Technologies raises €20 million ($22 million) in Series B round that brings in new investor, TUS-Holdings, alongside existing ones

Feb 14, 2020•over 5 years ago

Amount Raised

€20 Million

Round Type

series b

ParisBiotechnologyScience And EngineeringData And AnalyticsHealth CareSoftware

Description

 Stilla Technologies, a leading provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, has just raised €20 million ($22 million) in a Series B funding round that brought in a new investor, the Chinese group TUS-Holdings, alongside the participation of existing investors Illumina Ventures, Kurma Partners, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement and Idinvest Partners.

Company Information

Company

Stilla Technologies

Location

Paris, Ile De France, France

About

Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla’s groundbreaking Crystal Digital PCR™ solution, the naica® system, is the industry’s first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market. Stilla has U.S. headquarters in Boston, MA, European headquarters in Paris, France, and strategic distribution and business partnerships in China. To learn more, visit www.stillatechnologies.com and connect with Stilla on Twitter, LinkedIn and YouTube.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech